H

HaTay Pharmaceutical JSC
VN:DHT

Watchlist Manager
HaTay Pharmaceutical JSC
VN:DHT
Watchlist
Price: 90 600 VND -1.41% Market Closed
Market Cap: 7.5T VND
Have any thoughts about
HaTay Pharmaceutical JSC?
Write Note

EV/EBIT
Enterprise Value to EBIT

106.4
Current
14.8
Median
16.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
106.4
=
Enterprise Value
7.7T VND
/
EBIT
72B VND
All Countries
Close
EBIT Growth EV/EBIT to Growth
VN
H
HaTay Pharmaceutical JSC
VN:DHT
Average EV/EBIT: 1 820.9
106.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
22.7
22%
1
US
Johnson & Johnson
NYSE:JNJ
14.8
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.2
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
254
32%
7.9
CH
Novartis AG
SIX:NOVN
13.3
17%
0.8
US
Pfizer Inc
NYSE:PFE
16
19%
0.8

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A